ES2366342T3 - Heparina 2-o, 3-o desulfatada para el tratamiento del síndrome de trombocitopenia inducido por heparina (hit). - Google Patents

Heparina 2-o, 3-o desulfatada para el tratamiento del síndrome de trombocitopenia inducido por heparina (hit). Download PDF

Info

Publication number
ES2366342T3
ES2366342T3 ES05824840T ES05824840T ES2366342T3 ES 2366342 T3 ES2366342 T3 ES 2366342T3 ES 05824840 T ES05824840 T ES 05824840T ES 05824840 T ES05824840 T ES 05824840T ES 2366342 T3 ES2366342 T3 ES 2366342T3
Authority
ES
Spain
Prior art keywords
heparin
desulphated
medicament
anticoagulant
hit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05824840T
Other languages
English (en)
Spanish (es)
Inventor
Jeanine M. Walenga
Thomas Preston Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ParinGenix Inc
Original Assignee
ParinGenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ParinGenix Inc filed Critical ParinGenix Inc
Application granted granted Critical
Publication of ES2366342T3 publication Critical patent/ES2366342T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10—Heparin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
ES05824840T 2004-10-27 2005-10-26 Heparina 2-o, 3-o desulfatada para el tratamiento del síndrome de trombocitopenia inducido por heparina (hit). Expired - Lifetime ES2366342T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US974566 1997-11-19
US10/974,566 US7468358B2 (en) 2004-06-16 2004-10-27 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome

Publications (1)

Publication Number Publication Date
ES2366342T3 true ES2366342T3 (es) 2011-10-19

Family

ID=36228513

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05824840T Expired - Lifetime ES2366342T3 (es) 2004-10-27 2005-10-26 Heparina 2-o, 3-o desulfatada para el tratamiento del síndrome de trombocitopenia inducido por heparina (hit).

Country Status (9)

Country Link
US (1) US7468358B2 (enExample)
EP (1) EP1807095B1 (enExample)
JP (1) JP2008518090A (enExample)
AT (1) ATE507836T1 (enExample)
AU (1) AU2005299568A1 (enExample)
CA (1) CA2585640C (enExample)
DE (1) DE602005027883D1 (enExample)
ES (1) ES2366342T3 (enExample)
WO (1) WO2006047755A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11229664B2 (en) 2012-05-09 2022-01-25 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
WO2008106584A1 (en) * 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
WO2009015183A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
WO2009117677A2 (en) * 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
WO2011014793A2 (en) 2009-07-31 2011-02-03 Reliable Biopharmaceutical Corporation Process for preparing fondaparinux sodium and intermediates useful in the synthesis thereof
US8420790B2 (en) 2009-10-30 2013-04-16 Reliable Biopharmaceutical Corporation Efficient and scalable process for the manufacture of Fondaparinux sodium
DK3144325T3 (da) * 2010-09-14 2021-01-25 Univ Miyazaki Heparin med høj renhed og fremstillingsfremgangsmåde dertil
DK2646037T3 (en) * 2010-12-01 2019-03-04 Univ Australian National use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
WO2013016181A1 (en) * 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
WO2013115817A1 (en) 2012-02-02 2013-08-08 Reliable Biopharmaceutical Corporation An efficient and scalable process for the manufacture of fondaparinux sodium
AU2016234916A1 (en) * 2012-05-09 2016-11-17 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
CN107430137B (zh) 2015-03-03 2020-11-20 美国控股实验室公司 用于测量样品中的血清素的方法和系统
CA3102284A1 (en) * 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
GB202006960D0 (en) * 2020-05-12 2020-06-24 Aplagon Oy Therapeutic

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1164145B1 (en) * 1992-07-24 2007-12-05 Thomas P. Kennedy Non-anticoagulant desulfated heparins as medicaments
US5668118A (en) * 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5990097A (en) * 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
EP1128842B1 (en) * 1998-11-13 2006-03-15 Eli Lilly And Company Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia
WO2001019376A2 (en) 1999-09-13 2001-03-22 Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
WO2004050673A2 (en) 2002-11-27 2004-06-17 Massachusetts Institute Of Technology Methods for synthesizing polysaccharides
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20050282775A1 (en) * 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11229664B2 (en) 2012-05-09 2022-01-25 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression

Also Published As

Publication number Publication date
CA2585640A1 (en) 2006-05-04
CA2585640C (en) 2012-01-10
EP1807095B1 (en) 2011-05-04
US20070123489A1 (en) 2007-05-31
US7468358B2 (en) 2008-12-23
AU2005299568A1 (en) 2006-05-04
WO2006047755A2 (en) 2006-05-04
JP2008518090A (ja) 2008-05-29
EP1807095A2 (en) 2007-07-18
ATE507836T1 (de) 2011-05-15
WO2006047755A3 (en) 2007-02-01
EP1807095A4 (en) 2008-08-27
DE602005027883D1 (de) 2011-06-16

Similar Documents

Publication Publication Date Title
US20050282775A1 (en) Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7468358B2 (en) Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
Meara et al. Neutralizing the pathological effects of extracellular histones with small polyanions
US20060040896A1 (en) Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US5668118A (en) Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
ES2367778T3 (es) Derivados de glucosaminoglucanos parcialmente desulfatados como inhibidores de heparanasa, provistos de actividad antiangiogénica y desprovistos de efecto anticoagulante.
JPH06506685A (ja) 新規な非抗凝固剤ヘパリン誘導体
JP2010534672A (ja) 終末糖化産物受容体（ｒａｇｅ）の連結を阻止するための方法
US6489311B1 (en) Method for the prevention of apoptosis
EP2646037B1 (en) use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis.
US6127347A (en) Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
Kilgore et al. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart
Raimova et al. Anti-thrombotic action of sulfated polysaccharides on thrombosis caused by thromboplastin
JPH08508540A (ja) 循環血液量減少性ショックおよび関連ショック症候群の治療のための非抗凝血性の化学修飾したヘパリン様物質
PT1549337E (pt) Combinação de adnase i e glicosaminoglicanos para utilização em depuração de adn extracelular
AU763042B2 (en) Method of inhibiting NF-kappaB with heparin
WO2008140499A2 (en) Method for treating sepsis
AU4782493A (en) Medicameny for inhibiting neutrophil elastase and cathepsin
ES2234635T3 (es) Tratamiento de dolencias dependientes de angiogenesis con sulfato de dextrina.
ES2654816T3 (es) Uso del inhibidor C1 para la prevención de lesión de reperfusión de isquemia
JP2018524067A (ja) アンチトロンビン−ヘパリン組成物を利用する医療機器、システムおよび方法
US20070196347A1 (en) Methods for preventing neurological events
Maksimenko Effects of glycosaminoglycans in vascular events
JP2000344674A (ja) 血管内皮細胞増殖因子作用の抑制剤及び血管新生の抑制剤
JPH08301771A (ja) 腎疾患の予防または治療用製剤